Abstract
We studied the pharmacokinetics of glycopyrronium 11 uraemic patients undergoing cadaveric renal transplantation and in seven ASA I control patients undergoing general surgery. Glycopyrronium 4 μg kg-1 was given i.v. before induction of anaesthesia. Blood and urine samples were collected for up to 24 h for measurement of glycopyrronium concentrations using a radioreceptor assay. Volume of distribution in the elimination phase (Vβ) was similar in both groups, the elimination half-life T12β was longer (P <0.05), area under the plasma concentration-time curve (AUC) larger (P <0.01) and plasma clearance (Cl) smaller (P < 0.01) in the uraemic patients. In 3 h, mean 0.7 (range 0-3) % and 50 (21-82) % of glycopyrronium was excreted in the urine in the uraemic and healthy patients, respectively (P <0.001). The 24-h renal excretion was 7 (0-25) % in uraernic and 65 (30-99) % in control patients (P <0.001). We conclude that the elimination of glycopyrronium is severely impaired in uraemic patients. © 1993 British Journal of Anaesthesia.
Author supplied keywords
Cite
CITATION STYLE
Kirvelä, M., Ali-melkkilä, T., Kaila, T., Iisalo, E., & Lindgren, L. (1993). Pharmacokinetics of glycopyrronium in uraemic patients. British Journal of Anaesthesia, 71(3), 437–439. https://doi.org/10.1093/bja/71.3.437
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.